Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02546570 · ClinicalTrials.gov registry record · Phase 2
Oxytocin and Affect Processing in Posttraumatic Stress Disorder
A Phase 2 study of Posttraumatic Stress Disorder (PTSD), sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02546570: Completed Phase 2 study of Posttraumatic Stress Disorder (PTSD), sponsored by Yale University.
NCT02546570 is a Phase 2 study of Posttraumatic Stress Disorder (PTSD) that has completed, run by Yale University. The registered enrollment target is 11 participants, below the 111-participant average among 31 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02546570, a Phase 2 study of Posttraumatic Stress Disorder (PTSD), has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators plan to evaluate the influence of Oxytocin administration on affective processing in non-trauma exposed and trauma-exposed adults (both with and without posttraumatic stress disorder, PTSD).
Primary Outcome
Change in blood-oxygen-level dependent (BOLD) contrast signal in regions of interest relevant to fear/threat (e.g., decrease in amygdala activation) and reward processing (increase in ventral striatum activation) in oxytocin versus placebo sessions. Forearm brush stroking targets C-tactile (CT) nerves, which respond to gentle touch and engage the insula and cortical brain regions that mediate social-emotional processing. Palm brush stroking is the control condition, in that CT afferents do not
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
Connecticut
- Yale University - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
What the finished NCT02546570 record still lists
NCT02546570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 111-participant average among 31 other Posttraumatic Stress Disorder (PTSD) trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Posttraumatic Stress Disorder (PTSD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02546570 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02546570 about?
NCT02546570 is a clinical study titled "Oxytocin and Affect Processing in Posttraumatic Stress Disorder". The investigators will use multiple methods (including Oxytocin intranasal inhalation, neuroimaging, behavioral measures, peripheral hormone measurements) to examine how individuals' behavior, cognition, and brain function is impacted by the neuro-hormone Oxytocin. Specifically, the investigators pl...
What is the current status of trial NCT02546570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-08. Estimated completion is 2016-08.
What conditions does trial NCT02546570 study?
This clinical trial studies the following conditions: Posttraumatic Stress Disorder (PTSD).
What interventions are being tested in trial NCT02546570?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02546570?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02546570 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Posttraumatic Stress Disorder (PTSD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02546570's enrollment target sits among peer trials
11 30th of 31 higher than 2 of 31 other Posttraumatic Stress Disorder (PTSD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Posttraumatic Stress Disorder (PTSD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Suvorexant for Treatment of AUD and PTSD
RECRUITING · Phase 2
-
Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD
RECRUITING · Phase 2
-
Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders
COMPLETED · Phase 2
-
Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence
COMPLETED · Phase 2
-
Treatment for PTSD and Tinnitus
RECRUITING · NA
-
A Neurosensory Account of Anxiety and Stress (Study 2)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia